Anhui Anke Biotechnology (Group) Co (SZSE:300009) Piotroski F-Score: 6 (As of Aug. 31, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:300009 Anhui Anke Biotechnology (Group) Co Ltd SZSE:300009
90 GF Score
Price ¥8.43
GF Value ¥9.66
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Anhui Anke Biotechnology (Group) Co Piotroski F-Score?

Anhui Anke Biotechnology (Group) Co SZSE:300009 90 Piotroski F-Score is 6 as of Aug. 31, 2026, which is at its 10-year median of 6.00. GuruFocus rates SZSE:300009 with a GF Score™ of 90/100 and a GF Value™ of ¥9.66 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,338 Biotechnology companies, Anhui Anke Biotechnology (Group) Co ranks better than 92% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Anhui Anke Biotechnology (Group) Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Anhui Anke Biotechnology (Group) Co's Piotroski F-Score or its related term are showing as below:

SZSE:300009' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Anhui Anke Biotechnology (Group) Co was 8. The lowest was 4. And the median was 6.

Anhui Anke Biotechnology (Group) Co  (SZSE:300009) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Anhui Anke Biotechnology (Group) Co Piotroski F-Score Related Terms


Anhui Anke Biotechnology (Group) Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Anhui Anke Biotechnology (Group) Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anhui Anke Biotechnology (Group) Co Piotroski F-Score Chart

Anhui Anke Biotechnology (Group) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.00 5.00 4.00 8.00

Anhui Anke Biotechnology (Group) Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 8.00 7.00 6.00

SZSE:300009 vs VRTX, REGN, MRNA: Piotroski F-Score Comparison

For the Biotechnology subindustry, Anhui Anke Biotechnology (Group) Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anhui Anke Biotechnology (Group) Co Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anhui Anke Biotechnology (Group) Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Anhui Anke Biotechnology (Group) Co's Piotroski F-Score falls into.


SZSE:300009
90GF Score
Anhui Anke Biotechnology (Group) Co Ltd SZSE:300009
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was 184.966 + 183.709 + 167.588 + 164.743 = ¥701 Mil.
Cash Flow from Operations was 239.413 + 307.382 + 140.831 + 131.666 = ¥819 Mil.
Revenue was 670.402 + 683.93 + 541.716 + 556.179 = ¥2,452 Mil.
Gross Profit was 503.17 + 512.332 + 409.485 + 422.887 = ¥1,848 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(4922.963 + 5100.624 + 5547.653 + 5664.605 + 5126.157) / 5 = ¥5272.4004 Mil.
Total Assets at the begining of this year (Jun25) was ¥4,923 Mil.
Long-Term Debt & Capital Lease Obligation was ¥20 Mil.
Total Current Assets was ¥2,242 Mil.
Total Current Liabilities was ¥557 Mil.
Net Income was 173.587 + 117.228 + 209.002 + 157.515 = ¥657 Mil.

Revenue was 622.465 + 614.763 + 628.755 + 663.433 = ¥2,529 Mil.
Gross Profit was 477.44 + 469.021 + 483.868 + 503.992 = ¥1,934 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(4844.672 + 4990.978 + 5135.35 + 5104.226 + 4922.963) / 5 = ¥4999.6378 Mil.
Total Assets at the begining of last year (Jun24) was ¥4,845 Mil.
Long-Term Debt & Capital Lease Obligation was ¥32 Mil.
Total Current Assets was ¥2,081 Mil.
Total Current Liabilities was ¥619 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Anhui Anke Biotechnology (Group) Co's current Net Income (TTM) was 701. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Anhui Anke Biotechnology (Group) Co's current Cash Flow from Operations (TTM) was 819. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=701.006/4922.963
=0.14239514

ROA (Last Year)=Net Income/Total Assets (Jun24)
=657.332/4844.672
=0.13568142

Anhui Anke Biotechnology (Group) Co's return on assets of this year was 0.14239514. Anhui Anke Biotechnology (Group) Co's return on assets of last year was 0.13568142. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Anhui Anke Biotechnology (Group) Co's current Net Income (TTM) was 701. Anhui Anke Biotechnology (Group) Co's current Cash Flow from Operations (TTM) was 819. ==> 819 > 701 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=20.494/5272.4004
=0.00388703

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=31.5/4999.6378
=0.00630046

Anhui Anke Biotechnology (Group) Co's gearing of this year was 0.00388703. Anhui Anke Biotechnology (Group) Co's gearing of last year was 0.00630046. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=2241.744/556.799
=4.02612792

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=2080.676/619.41
=3.35912562

Anhui Anke Biotechnology (Group) Co's current ratio of this year was 4.02612792. Anhui Anke Biotechnology (Group) Co's current ratio of last year was 3.35912562. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Anhui Anke Biotechnology (Group) Co's number of shares in issue this year was 1647.429. Anhui Anke Biotechnology (Group) Co's number of shares in issue last year was 1590.287. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1847.874/2452.227
=0.75354932

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1934.321/2529.416
=0.76473028

Anhui Anke Biotechnology (Group) Co's gross margin of this year was 0.75354932. Anhui Anke Biotechnology (Group) Co's gross margin of last year was 0.76473028. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=2452.227/4922.963
=0.49812014

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=2529.416/4844.672
=0.52210263

Anhui Anke Biotechnology (Group) Co's asset turnover of this year was 0.49812014. Anhui Anke Biotechnology (Group) Co's asset turnover of last year was 0.52210263. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+0+0+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Anhui Anke Biotechnology (Group) Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Anhui Anke Biotechnology (Group) Co (SZSE:300009) has a Piotroski F-Score of 6 as of Aug. 31, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Anhui Anke Biotechnology (Group) Co and its competitors. This is near median its historical median of 6.00. Over the past decade, Anhui Anke Biotechnology (Group) Co's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Anhui Anke Biotechnology (Group) Co ranks #107 out of 1338 companies in the Biotechnology industry, placing it in the top 8%.
Is Anhui Anke Biotechnology (Group) Co's Piotroski F-Score too high?
Anhui Anke Biotechnology (Group) Co's current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Biotechnology industry median Piotroski F-Score is 3.00. Anhui Anke Biotechnology (Group) Co's value of 6 is 100% above this industry median. Based on the distribution chart, Anhui Anke Biotechnology (Group) Co ranks #107 out of 1338 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Anhui Anke Biotechnology (Group) Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anhui Anke Biotechnology (Group) Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anhui Anke Biotechnology (Group) Co ranks #107 out of 1338 companies for Piotroski F-Score. This places Anhui Anke Biotechnology (Group) Co in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Anhui Anke Biotechnology (Group) Co's value of 6 is 100% above this benchmark. Historically, Anhui Anke Biotechnology (Group) Co's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 3.00, Anhui Anke Biotechnology (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,338 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anhui Anke Biotechnology (Group) Co's current Piotroski F-Score of 6 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Anhui Anke Biotechnology (Group) Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anhui Anke Biotechnology (Group) Co's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anhui Anke Biotechnology (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Anhui Anke Biotechnology (Group) Co (SZSE:300009) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥9.66, compared to a current price of ¥8.43 — trading 12.7% below its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 100% above the Biotechnology industry median of 3.00. Anhui Anke Biotechnology (Group) Co's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Anhui Anke Biotechnology (Group) Co (SZSE:300009), the current Piotroski F-Score is 6 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anhui Anke Biotechnology (Group) Co (SZSE:300009) Overvalued in 2026?

Based on GuruFocus' analysis, Anhui Anke Biotechnology (Group) Co stock appears to be undervalued. The current stock price of ¥8.43 is trading 12.7% below its estimated GF Value™ of ¥9.66. GuruFocus considers Anhui Anke Biotechnology (Group) Co to be Modestly Undervalued.

Key valuation signals for SZSE:300009:

  • Piotroski F-Score: 6 (near median its 10-year median of 6.00)
  • GF Value™: ¥9.66 vs. price of ¥8.43 (12.7% below fair value)
  • GF Score™: 90/100 with 2 warning signs
  • Industry Position: 100% above the Biotechnology median (#107 of 1338)

No single metric tells the full story. See the SZSE:300009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Anhui Anke Biotechnology (Group) Co Business Description

Address No.9 Changjiang Road, Hefei High-tech Zone, Customs Road 669, Hefei, CHN, 230088
Anhui Anke Biotechnology (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceuticals and health-care products. The Company distributes its product in both domestic and overseas markets. The company operates in more than 30 provinces in China.
90GF Score

Get the complete analysis for SZSE:300009

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.43
Price
¥9.66
GF Value